STAAR Surgical Co
NASDAQ:STAA
Net Margin
STAAR Surgical Co
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
STAAR Surgical Co
NASDAQ:STAA
|
809.2m USD |
-25%
|
|
| CH |
|
Alcon AG
SIX:ALC
|
34.5B CHF |
11%
|
|
| JP |
|
Hoya Corp
TSE:7741
|
5.8T JPY |
23%
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
137.4B DKK |
16%
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.4B USD |
10%
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
5.8B GBP |
8%
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
5.5B CHF |
12%
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
44.8B CNY |
40%
|
|
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.6B USD |
17%
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
5.4B USD |
9%
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
6.7T KRW |
-253%
|
STAAR Surgical Co
Glance View
In the early throes of medical innovation, STAAR Surgical Co. carved a niche within the ophthalmic industry, where its focus on implantable lenses set it apart from many contemporaries. Based in Monrovia, California, the company began its journey by enhancing an integral component of human life: vision. Through the skillful development and manufacture of implantable collamer lenses (ICLs), STAAR Surgical has thrived by providing solutions for those seeking alternatives to laser-based surgeries. Its ICL technology directly targets issues like myopia (nearsightedness) and astigmatism, offering patients a reversible, less invasive option than traditional corrective procedures. STAAR Surgical's business model hinges on a blend of specialized technology and strategic market penetration. The company primarily generates revenue by selling its suite of implantable lenses to healthcare providers and clinics worldwide, capitalizing on the rising trend of elective vision correction procedures. With its innovation-driven credo, STAAR continually invests in R&D to enhance its product offerings, ensuring it remains at the forefront of eye-care technology. By targeting emerging markets and expanding its global footprint, particularly in regions with growing demand for premium vision solutions, STAAR has positioned its unique value proposition to capitalize on both technological advancements and changing patient preferences. Through this deliberate strategy, STAAR not only bolsters its revenue streams but also fortifies its presence as a key player in the ophthalmic landscape.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on STAAR Surgical Co's most recent financial statements, the company has Net Margin of -25.5%.
You don't have any saved screeners yet